LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis

Blood

Volumn 128, Issue 23, 2016, Pages 2694-2707

  Ceroi, Adam ^a,b,c,d   Masson, David ^d,e   Roggy, Anne ^a,b,c,d   Roumier, Christophe ^f   Chagué, Cécile ^a,b,c,d   Gauthier, Thierry ^a,b,c,d   Philippe, Laure ^a,b,c,d   Lamarthée, Baptiste ^a,b,c,d   Angelot Delettre, Fanny ^a,b,c,d   Bonnefoy, Francis ^a,b,c,d   Perruche, Sylvain ^a,b,c,d   Biichle, Sabeha ^a,b,c   Preudhomme, Claude ^f   MacIntyre, Elisabeth ^g   Lagrost, Laurent ^d,e   Garnache Ottou, Francine ^a,b,c,d   Saas, Philippe ^a,b,c,d  

^a RIGHT Interactions Hôte Greffon Tumeur Ingénierie Cellulaire et Génique   (France)

^b UNIVERSITÉ BOURGOGNE FRANCHE COMTÉ   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d Laboratoires d'Excellence Lipoprot eines et Sant e: Prev et Traitement des Maladies Inflammatoires et du Cancer   (France)

^e INSERM   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g INSTITUT NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; CHOLESTEROL; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; PROTEIN KINASE B; STAT5 PROTEIN; ABCA1 PROTEIN, HUMAN; ABCG1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; IL3 PROTEIN, HUMAN; INTERLEUKIN 3; LIVER X RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; CELL DEATH; CELL INFILTRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL EVALUATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPENIA; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THERAPY EFFECT; TUMOR XENOGRAFT; AGONISTS; ANIMAL; COMPARATIVE STUDY; DENDRITIC CELL; DRUG EFFECTS; DRUG SCREENING; FEMALE; MALE; METABOLISM; PATHOLOGY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP BINDING CASSETTE TRANSPORTER 1; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 1; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLESTEROL; DENDRITIC CELLS; FEMALE; HUMANS; INTERLEUKIN-3; LIVER X RECEPTORS; MALE; MICE; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-AKT; STAT5 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85015669653     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-06-724807     Document Type: Article

References (51)

1. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97(10): 3210-3217.
2. Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14(4): 220-222.
3. Dalle S, Beylot-Barry M, Bagot M, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010;162(1):74-79.
4. Martin-Martin L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7(9): 10174-10181.
5. Pileri A, Delfino C, Grandi V, Agostinelli C, Pileri SA, Pimpinelli N. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary. G Ital Dermatol Venereol. 2012;147(6):603-608.
6. Vitols S, Norgren S, Juliusson G, Tatidis L, Luthman H. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood. 1994;84(8):2689-2698.
7. Tatidis L, Gruber A, Vitols S. Decreased feedback regulation of low density lipoprotein receptor activity by sterols in leukemic cells from patients with acute myelogenous leukemia. J Lipid Res. 1997;38(12):2436-2445.
8. Oram JF, Vaughan AM. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res. 2006;99(10):1031-1043.
9. Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol. 2008;9(2):125-138.
10. Pommier AJ, Alves G, Viennois E, et al. Liver X receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene. 2010;29(18): 2712-2723.
11. Singh P, Saxena R, Srinivas G, Pande G, Chattopadhyay A. Cholesterol biosynthesis and homeostasis in regulation of the cell cycle. PLoS One. 2013;8(3):e58833.
12. Sun Y, Sukumaran P, Varma A, Derry S, Sahmoun AE, Singh BB. Cholesterol-induced activation of TRPM7 regulates cell proliferation, migration, and viability of human prostate cells. Biochim Biophys Acta. 2014;1843(9):1839-1850.
13. Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010;328(5986):1689-1693.
14. Murphy AJ, Akhtari M, Tolani S, et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest. 2011;121(10):4138-4149.
15. Garnache-Ottou F, Chaperot L, Biichle S, et al. Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood. 2005;105(3): 1256-1264.
16. Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385-392.
17. Pemmaraju N, Lane AA, Sweet KL, et al. Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): lead-in completed, expansion satge ongoing [abstract]. J Clin Oncol. 2016;34(15 suppl). Abstract 7006.
18. Im SS, Osborne TF. Liver x receptors in atherosclerosis and inflammation. Circ Res. 2011;108(8):996-1001.
19. Hong C, Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014;13(6):433-444.
20. Lin CY, Gustafsson JA. Targeting liver X receptors in cancer therapeutics. Nat Rev Cancer. 2015;15(4):216-224.
21. Wójcicka G, Jamroz-Wiśniewska A, Horoszewicz K, Bełtowski J. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig Med Dosw (Online). 2007;61:736-759.
22. Dove DE, Linton MF, Fazio S. ApoE-mediated cholesterol efflux from macrophages: separation of autocrine and paracrine effects. Am J Physiol Cell Physiol. 2005;288(3):C586-C592.
23. Hong C, Duit S, Jalonen P, et al. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J Biol Chem. 2010;285(26): 19720-19726.
24. Zhang L, Reue K, Fong LG, Young SG, Tontonoz P. Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis. Arterioscler Thromb Vasc Biol. 2012;32(11):2541-2546.
25. Ceroi A, Delettre FA, Marotel C, et al. The anti-inflammatory effects of platelet-derived microparticles in human plasmacytoid dendritic cells involve liver X receptor activation. Haematologica. 2016;101(3):e72-e76.
26. Garnache-Ottou F, Feuillard J, Ferrand C, et al; GOELAMS and GEIL study. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009;145(5):624-636.
27. Angelot-Delettre F, Biichle S, Ferrand C, et al. Intracytoplasmic detection of TCL1-but not ILT7-by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis. Cytometry A. 2012;81(8):718-724.
28. Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Contr. 2014;21(4):279-289.
29. Maeda T, Murata K, Fukushima T, et al. A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma. Int J Hematol. 2005;81(2): 148-154.
30. Chaperot L, Blum A, Manches O, et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol. 2006;176(1):248-255.
31. Ishibashi M, Filomenko R, Rébé C, et al. Knockdown of the oxysterol receptor LXRa impairs cholesterol efflux in human primary macrophages: lack of compensation by LXRb activation. Biochem Pharmacol. 2013;86(1):122-129.
32. Sapienza MR, Fuligni F, Agostinelli C, et al; AIRC 5xMille consortium 'Genetics-driven targeted management of lymphoid malignancies and the Italian Registry on Blastic Plasmacytoid Dendritic Cell Neoplasm. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia. 2014; 28(8):1606-1616.
33. Reddy EP, Korapati A, Chaturvedi P, Rane S. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene. 2000;19(21):2532-2547.
34. Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014; 2(1):4.
35. Zhuang J, Hawkins SF, Glenn MA, et al. Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. Haematologica. 2010; 95(1):110-118.
36. Schafranek L, Nievergall E, Powell JA, et al. Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia. 2015;29(1):76-85.
37. Zidovetzki R, Levitan I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim Biophys Acta. 2007;1768(6): 1311-1324.
38. Vedin LL, Lewandowski SA, Parini P, Gustafsson JA, Steffensen KR. The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. Carcinogenesis. 2009;30(4):575-579.
39. Vedin LL, Gustafsson JA, Steffensen KR. The oxysterol receptors LXRa and LXRb suppress proliferation in the colon. Mol Carcinog. 2013; 52(11):835-844.
40. Geyeregger R, Shehata M, Zeyda M, et al. Liver X receptors interfere with cytokine-induced proliferation and cell survival in normal and leukemic lymphocytes. J Leukoc Biol. 2009;86(5): 1039-1048.
41. Sanchez PV, Glantz ST, Scotland S, Kasner MT, Carroll M. Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors. Leukemia. 2014;28(4):749-760.
42. Agarwal JR, Wang Q, Tanno T, et al. Activation of liver X receptors inhibits hedgehog signaling, clonogenic growth, and self-renewal in multiple myeloma. Mol Cancer Ther. 2014;13(7): 1873-1881.
43. El Roz A, Bard JM, Huvelin JM, Nazih H. LXR agonists and ABCG1-dependent cholesterol efflux in MCF-7 breast cancer cells: relation to proliferation and apoptosis. Anticancer Res. 2012; 32(7):3007-3013.
44. Derangère V, Chevriaux A, Courtaut F, et al. Liver X receptor b activation induces pyroptosis of human and murine colon cancer cells. Cell Death Differ. 2014;21(12):1914-1924.
45. Rough JJ, Monroy MA, Yerrum S, Daly JM. Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells. J Ovarian Res. 2010;3:13.
46. Angelot-Delettre F, Roggy A, Frankel AE, et al. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. Haematologica. 2015;100(2):223-230.
47. Dagvadorj A, Kirken RA, Leiby B, Karras J, Nevalainen MT. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo. Clin Cancer Res. 2008;14(5):1317-1324.
48. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 1999;19(4):2690-2698.
49. Kirchgessner TG, Martin R, Sleph P, et al. Pharmacological characterization of a novel liver X receptor agonist with partial LXRa activity and a favorable window in nonhuman primates. J Pharmacol Exp Ther. 2015;352(2):305-314.
50. Hu B, Unwalla RJ, Goljer I, et al. Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist. J Med Chem. 2010;53(8):3296-3304.
51. Lim RK, Yu S, Cheng B, et al. Targeted delivery of LXR agonist using a site-specific antibody-drug conjugate. Bioconjug Chem. 2015;26(11): 2216-2222.